Immune checkpoints and immunotherapy for colorectal cancer.
Colorectal cancer (CRC) remains one of the major causes of death worldwide, despite steady improvement in early detection and overall survival over the past decade. Current treatment paradigms, with chemotherapy and biologics, appear to have reached their maximum benefit. Immunotherapy, especially with checkpoint inhibitors, has shown considerable clinical benefit in various cancers, including mismatch-repair-deficient CRC. This has led to the planning and initiation of several clinical trials evaluating novel immunotherapy agents-as single agents, combinations and in conjunction with chemotherapy-in patients with CRC. This article reviews biological and preclinical data for checkpoint inhibitors and discusses various immunotherapy trials in CRC, as well as current efforts in CRC immunotherapy.
Division of Oncology, Washington University School of Medicine, St. Louis, MO, USA and psingh@dom.wustl.edu.
Preet Paul
PP
Singh
Department of Surgery, Washington University School of Medicine, St. Louis, MO, USA.
Piyush K
PK
Sharma
Division of Oncology, Washington University School of Medicine, St. Louis, MO, USA and.
Gayathri
G
Krishnan
Division of Oncology, Washington University School of Medicine, St. Louis, MO, USA and.
A Craig
AC
Lockhart
checkpoint inhibition/blockade; colorectal cancer; cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4); immunotherapy; pembrolizumab; programmed death 1 (PD-1); vaccine